Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

HLB00620823a

PEACE

PEC

False

True

True

Coded

False

Clinical Trial

Open BioLINCC Study

Adult

Drug: angiotensin-converting enzyme inhibitors

2009-10-01

2009-10-01

2008-10-13

2008-01-15

November 1995 - June 2005

DCVS

Heart

non-HIV

non-COVID

0

0

No

No

No

Yes

Yes

Yes

Consent restricts use of biospecimens to research related to predictors of coronary heart disease progression.

Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Infarction
Myocardial Ischemia

To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.

Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)

Plasma
Serum
Urine